329 related articles for article (PubMed ID: 36252773)
1. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease.
Khanmohammadi S; Kuchay MS
Pharmacol Res; 2022 Nov; 185():106507. PubMed ID: 36252773
[TBL] [Abstract][Full Text] [Related]
2. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
Subramanian P; Hampe J; Tacke F; Chavakis T
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805998
[TBL] [Abstract][Full Text] [Related]
3. NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors.
Khanmohammadi S; Ramos-Molina B; Kuchay MS
Diabetes Metab Syndr; 2023 Jul; 17(7):102788. PubMed ID: 37302383
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease.
Chen S; Guo H; Xie M; Zhou C; Zheng M
Int Immunopharmacol; 2021 Aug; 97():107609. PubMed ID: 33887577
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms and Therapeutic Strategies for MAFLD Targeting TLR4 Signaling Pathways.
Ren G; Bai C; Yi S; Cong Q; Zhu Y
J Innate Immun; 2024; 16(1):45-55. PubMed ID: 38128497
[TBL] [Abstract][Full Text] [Related]
6. Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: An emerging therapeutic strategy.
Huang C; Zhou Y; Cheng J; Guo X; Shou D; Quan Y; Chen H; Chen H; Zhou Y
Front Endocrinol (Lausanne); 2023; 14():1145392. PubMed ID: 37020586
[TBL] [Abstract][Full Text] [Related]
7. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
Miura K; Ohnishi H
World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
Cornejo-Pareja I; Amiar MR; Ocaña-Wilhelmi L; Soler-Humanes R; Arranz-Salas I; Garrido-Sánchez L; Gutiérrez-Repiso C; Tinahones FJ
J Gastroenterol; 2024 Apr; 59(4):329-341. PubMed ID: 38265508
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).
Zhao Y; Zhou Y; Wang D; Huang Z; Xiao X; Zheng Q; Li S; Long D; Feng L
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139341
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor erythroid 2-related factor 2-mediated signaling and metabolic associated fatty liver disease.
Bukke VN; Moola A; Serviddio G; Vendemiale G; Bellanti F
World J Gastroenterol; 2022 Dec; 28(48):6909-6921. PubMed ID: 36632321
[TBL] [Abstract][Full Text] [Related]
12. New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk.
Yang K; Song M
Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764755
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of gut microbiota in patients with metabolic associated fatty liver disease.
Yang C; Xu J; Xu X; Xu W; Tong B; Wang S; Ji R; Tan Y; Zhu Y
Sci Rep; 2023 Jun; 13(1):9988. PubMed ID: 37340081
[TBL] [Abstract][Full Text] [Related]
14. Augmented hepatic Toll-like receptors by fatty acids trigger the pro-inflammatory state of non-alcoholic fatty liver disease in mice.
Sawada K; Ohtake T; Hasebe T; Abe M; Tanaka H; Ikuta K; Suzuki Y; Fujiya M; Hasebe C; Kohgo Y
Hepatol Res; 2014 Aug; 44(8):920-34. PubMed ID: 23834389
[TBL] [Abstract][Full Text] [Related]
15. The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions.
Alshehade S; Alshawsh MA; Murugaiyah V; Asif M; Alshehade O; Almoustafa H; Al Zarzour RH
Life Sci; 2022 Sep; 305():120732. PubMed ID: 35760093
[TBL] [Abstract][Full Text] [Related]
16. Macrophages in metabolic associated fatty liver disease.
Alharthi J; Latchoumanin O; George J; Eslam M
World J Gastroenterol; 2020 Apr; 26(16):1861-1878. PubMed ID: 32390698
[TBL] [Abstract][Full Text] [Related]
17. Influence of Gut Microbiota and its Metabolites on Progression of Metabolic Associated Fatty Liver Disease.
Wang YY; Lin HL; Wang KL; Que GX; Cao T; Zhu LM; Yang X; Yang XF
Chin Med Sci J; 2023 Dec; 38(4):286-296. PubMed ID: 38097345
[TBL] [Abstract][Full Text] [Related]
18. G protein-coupled receptors: Key molecules in metabolic associated fatty liver disease development.
López-Méndez I; Méndez-Maldonado K; Manzo-Francisco LA; Juárez-Hernández E; Uribe M; Barbero-Becerra VJ
Nutr Res; 2021 Mar; 87():70-79. PubMed ID: 33601216
[TBL] [Abstract][Full Text] [Related]
19. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies.
Frasinariu OE; Ceccarelli S; Alisi A; Moraru E; Nobili V
Dig Liver Dis; 2013 Jul; 45(7):543-51. PubMed ID: 23280158
[TBL] [Abstract][Full Text] [Related]
20. Infections at the nexus of metabolic-associated fatty liver disease.
Boeckmans J; Rombaut M; Demuyser T; Declerck B; Piérard D; Rogiers V; De Kock J; Waumans L; Magerman K; Cartuyvels R; Rummens JL; Rodrigues RM; Vanhaecke T
Arch Toxicol; 2021 Jul; 95(7):2235-2253. PubMed ID: 34027561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
